~~<i id='62219B68F2'><strike id='62219B68F2'><tt id='62219B68F2'><pre id='62219B68F2'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：knowledge 2025-10-09 00:08:45 Page View：535

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Resistance to opioid
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

When living in a high

Residentsofhigherfloorsmayhavereducedchancesofsurvivingamedicalemergency.HusseinMalla/APLivinginahig

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Illegal vapes are widely sold. Congress wants the FDA to stop it

SenateJudiciaryCommitteeChairmanDickDurbin(D-Ill.)speaksduringahearingoncombatingtheriseofillegale-c